Encyclopedia entry · enforcement watch
Melanotan
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-26
AI-friendly summary · Melanotan I and II
Melanotan I (afamelanotide, branded Scenesse) and Melanotan II are synthetic analogues of alpha-melanocyte-stimulating hormone (alpha-MSH). Melanotan I has a UK and EU marketing authorisation as Scenesse for erythropoietic protoporphyria, a rare condition. Melanotan II has no marketing authorisation anywhere. Melanotan II is the molecule typically sold as a research peptide for tanning effects, and the MHRA has been actively enforcing against UK consumer-facing sales since 2008.
Mechanism of action
How Melanotan works
Melanotan I (afamelanotide) and Melanotan II are synthetic analogues of alpha-melanocyte-stimulating hormone (alpha-MSH). Both act as agonists at melanocortin receptors. Melanotan I is selective for MC1R (the melanin-pigmentation receptor) and is the basis for the Scenesse licensed indication. Melanotan II has broader activity across MC1R, MC3R, MC4R, and MC5R, which is why its adverse-event profile includes effects beyond pigmentation, including blood-pressure changes, nausea, and central-nervous-system effects.
Source: EMA Scenesse (afamelanotide) marketing authorisation file
MHRA enforcement context
Melanotan II is the highest-enforcement-risk peptide covered on PeptideClear. The MHRA has issued multiple public warnings on Melanotan II since 2008. UK Trading Standards prosecutions have resulted in prison sentences for sellers. Adverse-event reports include severe nausea, blood-pressure changes, dysplastic naevi (atypical mole changes), and at least one cardiac event reportedly associated with the peptide. The legal position is that sale for human use is illegal under the Human Medicines Regulations 2012 when health claims are made.
- · The MHRA has issued multiple public warnings and enforcement actions on Melanotan II since 2008.
- · UK Trading Standards prosecutions on Melanotan II have resulted in prison sentences for sellers.
- · Adverse-reaction reports include severe nausea, blood pressure changes, dysplastic naevi, and at least one cardiac event reportedly associated with the peptide.
- · Sale for human use is illegal under the Human Medicines Regulations 2012 because it is an unlicensed medicinal product when health claims are made.
- · "Research use only" disclaimers are not a reliable shield for Melanotan II given the active MHRA focus on this molecule specifically.
- · Melanotan I (Scenesse) is licensed only for erythropoietic protoporphyria and is dispensed only via specialist clinicians, not via research-peptide retailers.
Why this entry is here
Melanotan II is the highest-enforcement-risk peptide we cover. We include it in the encyclopedia because UK readers searching for it deserve accurate information about the regulatory and safety position. We do not link to retailers from this page. The other research-peptide pages on the site link to retailer comparison; this one deliberately does not.
For erythropoietic protoporphyria specifically, Scenesse (Melanotan I) is the licensed UK route. Speak with a specialist clinician.
Risks and unknowns
What the literature does not yet show about Melanotan
Known concerns
- Melanotan II is an active MHRA enforcement target. UK Trading Standards prosecutions have resulted in prison sentences for sellers.
- Adverse-event reports include severe nausea, blood pressure changes, dysplastic naevi (atypical mole development), and at least one cardiac event reportedly associated with the peptide.
- Sale for human use is illegal under the Human Medicines Regulations 2012 when health claims are made.
- "Research use only" labelling is not a reliable shield for Melanotan II given the explicit MHRA focus on this molecule.
Open questions in the literature
- Long-term effects of repeated Melanotan II use on melanocytic lesions and skin cancer risk are not characterised in peer-reviewed RCT evidence.
- The cardiovascular safety profile of Melanotan II in non-clinical-trial populations is not formally established.
- Purity of black-market or research-tier Melanotan II is not publicly verifiable.
- Interactions of Melanotan II with hormonal contraceptives or cardiovascular medications have not been formally studied.
Regulatory note
Melanotan I (Scenesse) is licensed for erythropoietic protoporphyria only and dispensed by specialist clinicians. Melanotan II is unlicensed everywhere and an active MHRA enforcement target. Sale for human use is illegal under the Human Medicines Regulations 2012 when health claims are made.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Where to learn more
- · MHRA Drug Safety Update bulletins on gov.uk are the primary UK enforcement source.
- · Scenesse (afamelanotide) EMA marketing authorisation file for the licensed Melanotan I product.
- · PubMed: Melanotan II adverse events for the published safety case-report literature.
- · Adjacent compound: PT-141 (Bremelanotide) encyclopedia entry, the FDA-approved derivative.
Frequently asked questions
Is Melanotan legal in the UK?
What does the human evidence show for Melanotan?
What is the regulatory status of Melanotan in the UK?
Why does PeptideClear cover Melanotan if it is enforcement-risk?
Where can I learn more about Melanotan?
Clinical evidence record
Read the clinical evidence record for Melanotan
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy Melanotan in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.